Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14WZY | ISIN: US9034801012 | Ticker-Symbol: UNC0
Siehe auch UCB SA
Frankfurt
01.11.24
08:04 Uhr
87,50 Euro
-0,50
-0,57 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
UCB SA ADR Chart 1 Jahr
5-Tage-Chart
UCB SA ADR 5-Tage-Chart

Aktuelle News zur UCB SA ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrUCB's tau drug flunks phase 2 Alzheimer's trial days after Roche's exit from $120M bet35
22.10.Roche tosses out tau prospect, returning rights to UCB 4 years after placing $120M bet29
07.10.DelveInsight Business Research, LLP: The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight510UCB and Biogen reported encouraging topline findings from the Phase III PHOENYCS GO trial, which assessed dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in individuals with...
► Artikel lesen
04.10.Warnung vor Dosierfehlern!: Neue Spritze für Keppra und Levetiracetam UCB11
27.09.UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa9
24.09.UCB-Pipeline-Schätzungen "lassen Raum für Aufwärtspotenzial" - Citi26
24.09.UCB pipeline estimates 'leave risks to the upside' - Citi14
24.09.Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial4
24.09.Biogen, UCB mark late-stage trial win for autoimmune disease therapy8
24.09.Biogen, UCB get the lupus data they've waited two decades for4
24.09.Biogen, UCB report phase 3 lupus win, justifying risky bet on asset that failed earlier trial5
24.09.FDA approves UCB's BIMZELX for multiple inflammatory conditions2
24.09.UCB, Biogen lupus drug scores in phase 3 trial10
24.09.Biogen Inc.: UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024359Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary endpoints...
► Artikel lesen
23.09.UCB gets expanded FDA approval for psoriasis drug Bimzelx1
23.09.UCB rapidly bolsters blockbuster potential for Bimzelx with 3 new FDA approvals2
23.09.UCB: FDA Approves BIMZELX For Three New Indications5
23.09.UCB Announces U.S. FDA Approvals for BIMZELX (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis112With three new indications, BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases Approval...
► Artikel lesen
23.09.UCB rises on further Bimzelx approvals in the US8
29.08.Fierce Pharma Asia-Sanofi's flu shot setback; DualityBio's IPO plan; UCB's China asset sale4
Seite:  Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1